IVF breakthrough? lower progesterone dose tested in 1,020 women

NCT ID NCT05899010

Recruiting now Disease control Sponsor: Fundación Santiago Dexeus Font Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether a lower daily dose (600 mg) of vaginal progesterone works as well as the standard dose (800 mg) for supporting pregnancy after a frozen embryo transfer. About 1,020 women undergoing IVF will be randomly assigned to one of the two doses. The main goal is to see if ongoing pregnancy rates at 11-13 weeks are similar between groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vaginal micronized progesterone
What this could lead to: If this works, it could show that a lower dose of progesterone is just as effective for supporting pregnancy after frozen embryo transfer, potentially reducing side effects and cost.
What could go wrong: This is a non-inferiority trial, so it may only confirm that the new dose is not worse than the standard, not necessarily better. Results may not apply to all IVF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFERTILITY

Contacts and locations

Locations

Hospital Universitario Quiron Dexeus
RECRUITING

Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.